- Home
- NMM vs PRTA Comparison
NMM vs PRTA Comparison
Compare NMM & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMM
- PRTA
- Stock Information
- Founded
- NMM 2007
- PRTA 2012
- Country
- NMM Greece
- PRTA Ireland
- Employees
- NMM N/A
- PRTA N/A
- Industry
- NMM Marine Transportation
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- NMM Consumer Discretionary
- PRTA Health Care
- Exchange
- NMM Nasdaq
- PRTA Nasdaq
- Market Cap
- NMM 959.8M
- PRTA 809.8M
- IPO Year
- NMM 2007
- PRTA N/A
- Fundamental
- Price
- NMM $39.20
- PRTA $4.59
- Analyst Decision
- NMM Strong Buy
- PRTA Buy
- Analyst Count
- NMM 1
- PRTA 9
- Target Price
- NMM $80.00
- PRTA $27.67
- AVG Volume (30 Days)
- NMM 83.5K
- PRTA 2.8M
- Earning Date
- NMM 05-07-2025
- PRTA 05-08-2025
- Dividend Yield
- NMM 0.51%
- PRTA N/A
- EPS Growth
- NMM N/A
- PRTA N/A
- EPS
- NMM 11.23
- PRTA N/A
- Revenue
- NMM $1,319,623,000.00
- PRTA $137,935,000.00
- Revenue This Year
- NMM N/A
- PRTA N/A
- Revenue Next Year
- NMM $7.93
- PRTA $122.59
- P/E Ratio
- NMM $3.49
- PRTA N/A
- Revenue Growth
- NMM 0.28
- PRTA 54.55
- 52 Week Low
- NMM $28.37
- PRTA $4.32
- 52 Week High
- NMM $65.89
- PRTA $25.42
- Technical
- Relative Strength Index (RSI)
- NMM 58.59
- PRTA 19.53
- Support Level
- NMM $37.81
- PRTA $4.32
- Resistance Level
- NMM $39.90
- PRTA $4.94
- Average True Range (ATR)
- NMM 1.15
- PRTA 0.52
- MACD
- NMM -0.07
- PRTA -0.15
- Stochastic Oscillator
- NMM 37.77
- PRTA 7.24
About NMM Navios Maritime Partners LP Common Units Representing Limited Partner Interests
Navios Maritime Partners LP is a seaborne shipping company. It owns and operates dry cargo and container vessels with the primary long-term and staggered expiration charters. The firm's fleet consists of Ultra- Handymax, Panamax, Capsize, and Container vessels and categorized in Drybulk and Container vessels. It earns revenue through the chartering of vessels and voyage contracts. Geographically, it generates majority revenue from Asia.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).